In Europe, the European Medicines Agency estimates that up to 36 million people are diagnosed with an RD. However, approximately 5 per cent of RDs have US FDAapproved treatment options, while up to 15 per cent have at least one drug that exhibits potential for treatment, diagnosis, or prevention. The growing number of unaddressed RD needs is a major catalyst for R&D. There is a need for novel medicine to treat RDs that currently have limited therapeutic choices. Let's explore further.
Governments across the world have regulatory incentives to support orphan drug (OD) development. It is more appealing for pharmaceutical firms to engage in R&D for RDS because of these incentives, which include prolonged exclusivity, tax benefits, and simplified and expedited regulatory procedures and approvals.
Recent advancements in precision medicine and informatics, such as big data analytics, multi-omics, nanomedicine, gene-editing techniques, and nextgeneration diagnostics, have created opportunities to develop specific and individualised therapies for RDs. The convergence of cancer and RDs is becoming evident. Precision oncology and tailored medicine for rare tumours are emerging as prominent themes in the discipline, facilitating the OD industry's expansion.
There are multiple challenges restraining the development and adoption of orphan drugs. Owing to low awareness of RDs, many patients go undetected for extended periods. Apart from diagnosis, both prognostics and therapy are seeing significant gaps that must be filled. Challenges in prognosis assessment are due to the absence of reliable parameters to measure improvement and/or biomarkers as well as a lack of knowledge of underlying pathophysiological pathways.
Furthermore, a limited patient sample size prevents the derivation of statistically significant parameters.
Bu hikaye Bio Spectrum dergisinin August 2024 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Giriş Yap
Bu hikaye Bio Spectrum dergisinin August 2024 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Giriş Yap
Early Diabetic Retinopathy Detection Remains a Challenge
The Vitreo Retinal Society of India (VRSI) and the Research Society for the Study of Diabetes in India (RSSDI) have formulated a first-of-its kind diabetic retinopathy (DR) screening guideline to help physicians and diabetologists in India educate their patients about DR.
Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time
US-based Promega Corporation, a life-sciences research partner dedicated to providing intuitive tools that empower scientists to innovate, has unveiled the new GloMax Galaxy Bioluminescence Imager.
Qiagen launches QIAcuityDx digital PCR system for clinical testing in oncology
Qiagen N.V. has announced the launch of the QIAcuityDx Digital PCR System, a pivotal addition to its digital PCR portfolio now expanding into clinical diagnostics.
Thermo Fisher introduces iCAP MX Series ICP-MS to simplify trace elemental analysis
Thermo Fisher Scientific Inc. has launched the Thermo Scientific iCAP MX Series ICP-MS to simplify trace element analysis with inductively coupled plasma mass spectrometry (ICP-MS).
Singleron, Bioscreen to enhance access to single cell multi-omics solutions for Indian researchers
Singleron Biotechnologies, a leading innovator in single cell multi-omics solutions, has announced a strategic partnership with Bioscreen, a renowned distributor of advanced life science products in India.
IIT Madras identifies enhanced drug delivery method for eye treatments
Researchers at the Indian Institute of Technology Madras (IIT-M) have demonstrated how drugs injected in the human eye can be better delivered to the target region through ‘convection caused by mild laser heating’.
IIT Madras develops indigenous POCUS scanner for sports injury diagnosis
A team of researchers at the Indian Institute of Technology Madras (IIT-M) has developed an indigenous portable Point-of-Care-Ultrasound (POCUS) Scanner for sports injury diagnosis and management.
Practo strengthens Board with appointment of TVG Krishnamurthy and Dr Alexander Kuruvilla
Practo has appointed two new directors to its board: TVG Krishnamurthy and Dr Alexander Kuruvilla.
Dr R N Gupta steps in as National President of Indian Pharmaceutical Association
Dr R N Gupta has been elected as the National President of the Indian Pharmaceutical Association (IPA), the oldest and largest association of pharmaceutical professionals in the country, for the term 2024 - 2026 (October 1, 2024 - September 30, 2026).
QR678 brings medtech leader Sridhar Ranganathan to advisory board
QR678, a pioneering company dedicated to revolutionising hair and skin science through groundbreaking research and innovative solutions, has announced the appointment of Sridhar Ranganathan to its Board of Advisors.